Detail akcie Shionogi & Co online

Business Summary: Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.
Financial Summary: BRIEF: For the fiscal year ended 31 March 2025, Shionogi & Co Ltd revenues increased 1% to Y438.27B. Net income increased 5% to Y170.44B. Revenues reflect UK segment increase of 22% to Y245.51B, Americas excl. USA segment increase of 30% to Y23.44B. Net income benefited from Impairment Loss - Non-Operating Expense decrease of 96% to Y471M (expense), Special severance payment decrease of 88% to Y860M (expense).